Grant Funding

We work with patient advocates, nonprofits, and healthcare professionals across all our therapeutic areas to improve lives through science.

Choose your region to learn more.

Contact Us

grants@gilead.com | phone: 650-522-1696650-522-1696 | Fax: 650-522-1707

Group of students talking in classroom

Giving in North America

What We Fund

Gilead is inspired by the work that our grantees do every day to improve access and eliminate barriers to healthcare, advance education among patients and healthcare professionals, and help build strong local communities. Gilead supports projects across all of our therapeutic areas — HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.

United States, Canada

1.2 million+ people in the U.S. have HIV; 15% don’t know they’re infected

Continual advances in medical research help millions of people living with HIV have longer, more fulfilling lives today. But HIV continues to have a devastating impact, especially on people who belong to underserved communities and who lack access to medical care. Gilead supports organizations working to help individuals learn their status and get the care they need. We also support organizations that aim to solve the challenges of tomorrow, including how to:

  • Understand the impact HIV has on an aging population
  • Ensure continuity and retention in care
  • Spark appreciation for innovative thinking in HIV treatment
  • Identify and create a new generation of advocates
Red HIV ribbon

Gilead works to address the HIV epidemic by discovering transformative and life-saving medicines, developing simplified treatment regimens that increase efficacy, expanding access to treatment for those who need it most and building communities among people affected by HIV and AIDS. Continuing on this commitment, Gilead will partner with and support institutions, community groups and organizations that are engaged in HIV cure activities by providing grant funding.

About 38,000 new cases of HIV are reported in the U.S. each year

More tools than ever are now available to help prevent HIV infection. Yet about 40,000 new cases of HIV are still reported in the U.S. each year. Gilead supports the efforts of community-based organizations, public health entities and similar nonprofit organizations to educate their constituents about comprehensive HIV prevention, including the role of pre-exposure prophylaxis (PrEP). Specifically, Gilead supports programs designed to:

  • Provide comprehensive education on the range of prevention options and strategies available
  • Ensure biomedical prevention plans, such as PrEP, are implemented safely and effectively in accordance with recommended guidelines
  • Engage communities and individuals at highest risk for HIV infection in prevention efforts
About 3.5 million peoplein the U.S. have chronic hepatitis C, and most are unaware they’re infected

Each year, more Americans die from Hepatitis C than HIV. Yet public awareness of this disease remains limited because of its disproportionate impact on drug users, minorities and other at-risk groups. Gilead is working to change this by funding organizations that raise awareness of the importance of testing and access to care among these groups, as well as those that:

  • Look for ways to increase treatment capacity and sustainability
  • Move individuals down the care pathway from screening to cure
  • Eliminate intrinsic barriers to care and treatment
Approximately 1 person in the U.S. is diagnosed with a blood cancer every 3 minutes

Most adults in the U.S. have met or have known at least one cancer victim or survivor. Cancer remains one of the greatest health challenges we face, especially as the population ages. While there is no cure yet, education and awareness are powerful tools for detecting and treating the disease, and Gilead supports organizations that work to:

  • Improve health literacy, enabling individuals affected by cancer to make informed health decisions
  • Educate healthcare providers on identification, screening and diagnosis
  • Improve access to treatment by overcoming financial and other obstacles
1 in 31 Americans unknowingly carry the defective cystic fibrosis gene

From cystic fibrosis (CF) to influenza, inflammatory and respiratory diseases have a substantial impact on people of every age, gender, ethnic group and economic class. Gilead funds organizations that work in this therapeutic area to:

  • Improve individuals’ health literacy, enabling them to make informed health decisions
  • Educate healthcare providers on identification, screening and diagnosis
  • Improve access to treatment by overcoming financial and other obstacles
Older woman looking at camera

Giving in Latin America & the Caribbean

What We Fund

For many years, Gilead has worked with local partners to provide our medicines throughout Latin America and the Caribbean. Gilead therapies continue to address unmet medical needs in the region, bringing innovative and life-saving treatments to communities in Argentina, Belize, Brazil, Haiti, Jamaica and elsewhere. The efforts of our corporate contributions team build upon our overall mission, as we identify and support organizations that seek to:

  • Improve access to healthcare
  • Reduce disparities for disadvantaged groups
  • Advance education among patients and healthcare professionals
  • Support local communities

In Latin America and the Caribbean, funding priority is given to projects within Gilead’s therapeutic areas of HIV and liver diseases.

Anguilla, Antigua and Barbuda, Argentina, Aruba, the Bahamas, Barbados, Belize, Bolivia, Brazil, British Virgin Islands, Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curacao, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Saint Maarten, St. Kitts and Nevis, St. Lucia, St. Vincent & The Grenadines, Suriname, Trinidad and Tobago, Turks and Caicos Islands, Uruguay, Venezuela

Aguaruna people of Peru are infected with HIV at 10 x the rate of the overall country

Gilead places a strong emphasis on combating the HIV epidemic in Latin America and the Caribbean. Despite advancements in medicines and treatments, HIV’s devastating and inequitable impact remains, particularly among indigenous people living in remote regions of Peru as well as young people throughout Latin America. In the Caribbean, more than 230,000 people are living with the disease, making the region’s HIV prevalence the second highest of anywhere in the world.

In other populous areas, the social stigma of HIV-positive status leads many to decline treatment or travel great distances to be treated outside their community. Elsewhere, poor treatment options for incarcerated populations (a group that faces systemic barriers to receiving quality HIV care) leads to public health concerns as individuals complete their rehabilitation programs and re-enter society.

Gilead supports organizations working to help individuals learn their status and get the care they need. We also fund groups looking to meet the unique needs of the region, including:

  • Increasing awareness and understanding of HIV incidence and treatment methods
  • Facilitating medicine provision and local provider expertise
  • Supporting linkage to care programs
  • Identifying and fostering prevention programs for at-risk individuals; for example, via pre-exposure prophylaxis (PrEP)
An estimated 70% of HCV cases in Latin America are undiagnosed

Treating Hepatitis B (HBV), Hepatitis C (HCV) and other forms of liver disease can be a challenge in Latin America and the Caribbean for a variety of reasons. One critical difficulty centers on reaching at-risk groups with screening and diagnosis. The estimated percentage of undiagnosed individuals living with HCV in Latin America and the Caribbean has gone unchanged over the span of many years. Lack of disease awareness and diagnosis options have contributed to the persistence of this gap. Even in areas where intravenous drug use and other behaviors that can increase risk are better understood, many hospital procedures are not performed in sterile conditions, with individuals contracting viral hepatitis in the process.

Our grantee partners seek to increase awareness of risk factors and the educational tools available to patient communities throughout the region. Gilead also funds projects to improve diagnostics and build medical specialization in HBV and HCV.

Gilead is working to improve the overall continuum of care for liver diseases by funding organizations that:

  • Ensure providers have the training and expertise they need to deliver proper care
  • Improve infrastructure and screening ability of regions where care is dependent on viral load
  • Reduce undiagnosed totals
  • Increase awareness of risk factors

Though priority is given to projects related to HIV- and liver disease-related projects, Gilead will consider grant proposals outside of these therapeutic areas, provided they conform to our eligibility restrictions. These proposals may include (but are not limited to):

  • Access and education surrounding antifungal treatments
  • Social services (homeless shelters, food banks, etc.)
  • Community vibrancy projects (STEM education, arts support, community beautification, etc.)
Man and woman in front of Parliament and the Thames in London

Giving in Europe

The Gilead international headquarters are located in Stockley Park, United Kingdom. The company maintains offices across Europe and collaborates with regional partners in the Middle East. Gilead has supported healthcare and charitable activities in the EMEA region for many years.

United Kingdom, Austria, Benelux, Czech Republic, Denmark, France, Finland, Germany, Greece, Ireland, Italy, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Turkey

Our grantmaking in EMEA focuses on all of our core therapeutic areas:

  • HIV/AIDS
  • Viral Hepatitis
  • Hematology and cancer
  • Inflammatory and respiratory diseases

Within these therapeutic areas, we provide support for a broad range of activities, including:

  • Disease awareness
  • Disease prevention
  • Professional education
  • Improving patient access to care
  • Improving quality of care
Small boy loking at the camera and smiling

Giving in Africa

Across Africa, Gilead works with a number of local partners to help ensure that our medicines reach the people that need them. Our pioneering generic licensing agreements have played a central role in expanding access to high-quality, low-cost HIV treatment throughout Africa. We recently established an office in South Africa to manage our partnerships in the region.

Countries Supported: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic (CAR), Chad, Comoros, Democratic Republic of the Congo, Republic of the Congo, Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome & Pr., Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe

Our grantmaking in Africa focuses on the following therapeutic areas:

  • HIV/AIDS
  • Viral Hepatitis

Within these therapeutic areas, we provide support for a broad range of activities, including:

  • Disease awareness
  • Disease prevention
  • Professional education
  • Improving patient access to care
  • Improving quality of care
  • Increasing scientific capacity
  • Strengthening healthcare systems
Mother and small child playing in garden

Giving in Asia

Gilead has operations across Asia, with a regional presence in Hong Kong, standalone business operations in mainland China and Japan, and local collaborations in emerging markets across the region.

Learn more about the Asia Rainbow Grant

Afghanistan, Bangladesh, Bhutan, Cambodia, China, Fiji, Hong Kong, India, Indonesia, Kiribati, Kyrgyz Republic, Lao PDR, Malaysia, Maldives, Mongolia, Myanmar, Nauru, Nepal, Pakistan, Palau, Papua New Guinea, Philippines, Samoa, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Tajikistan, Thailand, Timor-Leste, Tonga, Turkmenistan, Truvalu, Uzbekistan, Vanuatu, Vietnam.

Our grantmaking in Asia focuses on the following therapeutic areas:

  • HIV/AIDS
  • Viral Hepatitis

Within these therapeutic areas, we provide support for a broad range of activities, including:

  • Disease awareness
  • Disease prevention
  • Professional education
  • Improving patient access to care
  • Improving quality of care
  • Increasing scientific capacity
  • Strengthening healthcare systems
Girl listening to music, leaning against a van, near water

Giving in Australia

Our office in Australia has supported local healthcare and charitable activities in the region for many years.

Australia, New Zealand

Our grantmaking in Australia focuses on all of our core therapeutic areas:

  • HIV/AIDS
  • Viral Hepatitis
  • Hematology and cancer
  • Inflammatory and respiratory diseases

Within these therapeutic areas, we provide support for a broad range of activities, including:

  • Disease awareness
  • Disease prevention
  • Professional education
  • Improving patient access to care
  • Improving quality of care